Impact of macular fluid volume fluctuations on visual acuity during anti-VEGF therapy in eyes with nAMD
- PMID: 33414525
- PMCID: PMC8526705
- DOI: 10.1038/s41433-020-01354-4
Impact of macular fluid volume fluctuations on visual acuity during anti-VEGF therapy in eyes with nAMD
Abstract
Objectives: To study the effect of repeated retinal thickness fluctuations during the anti-VEGF therapy maintenance phase in neovascular age-related macular degeneration (nAMD).
Methods: Data were extracted from electronic medical records of 381 nAMD patients, aged ≥50 years; baseline VA ≥33 and ≤73 letters; ≥24 months' follow-up and ≥2 optical coherence tomography (OCT) measurements. OCT scans were analysed using an artificial intelligence algorithm that quantified the volumes of intraretinal fluid (IRF), subretinal fluid (SRF), pigment epithelial detachments (PED) and central subfield thickness (CSFT). IRF, SRF and PED were summed to obtain total fluid (TF). The standard deviation (SD) of IRF, SRF, PED, CSFT and TF was computed and categorised into quartiles (SD-Q). Relationships between SD-Qs for each OCT feature and VA change was tested using generalised estimating equations and linear regression.
Results: By Month 24, compared to SD-Q1, eyes in SD-Q2, SD-Q3, and SD-Q4 for IRF, SRF, PED, CSFT and TF showed greater VA losses. Eyes in SD-Q4 of TF were 9.4 letters worse compared to eyes in Q1 (95% Confidence Interval: -12.9 to -6.0). The frequency of clinic visits with IRF and SRF present on OCT scans by quartiles of CSFT was lower in eyes with least fluctuation (Q1) compared to eyes with the most fluid fluctuation (Q4) (median [IQR] IRF: 0.3 [0.0-0.7] versus 0.8 [0.5-1.0]; SRF: 0.0 [0.0-0.5] versus 0.6 [0.3-1.0]).
Conclusions: Greater fluctuations in retinal fluid volumes during the maintenance phase of anti-VEGF treatment in nAMD is associated with worse VA by 2 years.
© 2021. The Author(s).
Conflict of interest statement
UC received travel support from Novartis for attendance at a meeting where these data were presented and has received honoraria from Novartis Pharma AG and Bayer AG. NP and EW are employees of IQVIA. MH and GB are employees of Notal Vision. CB, AnS and AS are employees of Novartis Pharma AG.
Figures


Similar articles
-
Short-term response to anti-VEGF as indicator of visual prognosis in refractory age-related macular degeneration.Eye (Lond). 2024 May;38(7):1342-1348. doi: 10.1038/s41433-023-02900-6. Epub 2024 Jan 26. Eye (Lond). 2024. PMID: 38279038 Free PMC article.
-
Macular Morphology and Visual Acuity in the Second Year of the Comparison of Age-Related Macular Degeneration Treatments Trials.Ophthalmology. 2016 Apr;123(4):865-75. doi: 10.1016/j.ophtha.2015.12.002. Epub 2016 Jan 9. Ophthalmology. 2016. PMID: 26783095 Free PMC article. Clinical Trial.
-
Artificial intelligence-based fluid quantification and associated visual outcomes in a real-world, multicentre neovascular age-related macular degeneration national database.Br J Ophthalmol. 2024 Jan 29;108(2):253-262. doi: 10.1136/bjo-2022-322297. Br J Ophthalmol. 2024. PMID: 36627173
-
Association Between Visual Acuity and Residual Retinal Fluid Following Intravitreal Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration: A Systematic Review and Meta-analysis.JAMA Ophthalmol. 2022 Jun 1;140(6):611-622. doi: 10.1001/jamaophthalmol.2022.1357. JAMA Ophthalmol. 2022. PMID: 35551359 Free PMC article.
-
Defining response to anti-VEGF therapies in neovascular AMD.Eye (Lond). 2015 Jun;29(6):721-31. doi: 10.1038/eye.2015.48. Epub 2015 Apr 17. Eye (Lond). 2015. PMID: 25882328 Free PMC article. Review.
Cited by
-
Efficacy and safety of treat-and-extend intravitreal brolucizumab in naive and switched patients with macular neovascularization: one-year follow-up study.BMC Ophthalmol. 2024 Oct 4;24(1):436. doi: 10.1186/s12886-024-03706-0. BMC Ophthalmol. 2024. PMID: 39367347 Free PMC article.
-
Short-term response to anti-VEGF as indicator of visual prognosis in refractory age-related macular degeneration.Eye (Lond). 2024 May;38(7):1342-1348. doi: 10.1038/s41433-023-02900-6. Epub 2024 Jan 26. Eye (Lond). 2024. PMID: 38279038 Free PMC article.
-
Characteristics of Eyes With Neovascular Age-Related Macular Degeneration Requiring Frequent Anti-vascular Endothelial Growth Factor Injections.Cureus. 2023 Dec 20;15(12):e50817. doi: 10.7759/cureus.50817. eCollection 2023 Dec. Cureus. 2023. PMID: 38249251 Free PMC article.
-
One-year visual and anatomical outcomes of intravitreal faricimab injection for neovascular age-related macular degeneration after prior brolucizumab treatment.Sci Rep. 2024 Apr 20;14(1):9087. doi: 10.1038/s41598-024-59894-8. Sci Rep. 2024. PMID: 38643252 Free PMC article.
-
Characterising treatment outcomes of patients achieving quarterly aflibercept dosing for neovascular age-related macular degeneration: real-world clinical outcomes from a large tertiary care centre.Eye (Lond). 2023 Mar;37(4):779-784. doi: 10.1038/s41433-022-02220-1. Epub 2022 Sep 9. Eye (Lond). 2023. PMID: 36085360 Free PMC article.
References
-
- Samalia P, Garland D, Squirrell D. Nurse specialists for the administration of anti-vascular endothelial growth factor intravitreal injections. N Z Med J. 2016;129:32–38. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous